| |
HMP form
|
|---|
|
Indication
|
Total
|
Oral solution
|
Tablets
|
|---|
|
System Organ Class / Preferred Term
|
(N = 634)
|
(N = 421)
|
(N = 213)
|
|---|
|
Infections and infestation
|
475 (74.9%)
|
326 (77.4%)
|
149 (70.0%)
|
|
Urinary tract infection
|
216 (34.1%)
|
171 (40.6%)
|
45 (21.1%)
|
|
Pyelonephritis chronica
|
80 (12.6%)
|
40 (9.5%)
|
40 (18.8%)
|
|
Cystitis
|
72 (11.4%)
|
39 (9.3%)
|
33 (15.5%)
|
|
Pyelonephritisa
|
71 (11.2%)
|
50 (11.9%)
|
21 (9.9%)
|
|
Pyelonephritis acutea
|
39 (6.2%)
|
29 (6.9%)
|
10 (4.7%)
|
|
Renal and urinary disorders
|
225 (35.5%)
|
136 (32.3%)
|
89 (41.8%)
|
|
Hyperoxaluria
|
106 (16.7%)
|
73 (17.3%)
|
33 (15.5%)
|
|
Hypercalciuria
|
31 (4.9%)
|
20 (4.8%)
|
11 (5.2%)
|
|
Calculus urinary
|
23 (3.6%)
|
12 (2.9%)
|
11 (5.2%)
|
|
Haematuria
|
23 (3.6%)
|
15 (3.6%)
|
8 (3.8%)
|
- aPyelonephritis was classified in case it was not further specified by the physician whether acute or chronic pyelonephritis was present
